NZ758480A - Compositions and methods for immunooncology - Google Patents
Compositions and methods for immunooncologyInfo
- Publication number
- NZ758480A NZ758480A NZ758480A NZ75848016A NZ758480A NZ 758480 A NZ758480 A NZ 758480A NZ 758480 A NZ758480 A NZ 758480A NZ 75848016 A NZ75848016 A NZ 75848016A NZ 758480 A NZ758480 A NZ 758480A
- Authority
- NZ
- New Zealand
- Prior art keywords
- nucleic acid
- molecule
- grna
- grna molecule
- car
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is directed to a gRNA molecule comprising a tracr and crRNA, wherein the crRNA comprises a targeting domain complementary to a target sequence of T Cell Receptor Alpha (TRAC).
Claims (17)
1. A gRNA le comprising a tracr and crRNA, wherein the crRNA comprises a targeting domain that is complementary to a target sequence of T Cell Receptor Alpha (TRAC), wherein the ing domain comprises SEQ ID NO: 5528.
2. The gRNA molecule of claim 1, wherein the ing domain and the tracr are disposed on separate nucleic acid molecules.
3. The gRNA molecule of claim 1, wherein the targeting domain and the tracr are disposed on a single nucleic acid molecule, and wherein the tracr is disposed 3’ to the targeting domain.
4. The gRNA molecule of any one of claims 1 to 3, comprising: (a) one or more phosphorothioate modification(s) at the 3’ end of a c acid molecule; (b) one or more phosphorothioate modification(s) at the 5’ end of a nucleic acid molecule; (c) one or more 2’-O-methyl cation(s) at the 3’ end of a nucleic acid molecule; (d) one or more 2’-O-methyl modification(s) at the 5’ end of a nucleic acid molecule; (e) one or more 2’ yl cation at each of the 4th-to-terminal, 3rd-toterminal , and 2nd-to-terminal 3’ residues of a nucleic acid molecule; or (f) any combination thereof.
5. A composition comprising a first gRNA molecule of any one of claims 1 to 4, and a Cas9 molecule or a nucleic acid encoding the Cas9 molecule, n the gRNA molecule and the Cas9 molecule are present in a ribonuclear protein complex (RNP).
6. The composition of claim 5, wherein the Cas9 molecule comprises any one of SEQ ID NO: 6611 or SEQ ID NO: 7821 to SEQ ID NO: 7831, or a sequence having at least 95% homology thereto.
7. The composition of claim 5 or claim 6, further comprising a second gRNA molecule; a second gRNA molecule and a third gRNA molecule; or a second gRNA molecule, a third gRNA le, and a fourth gRNA molecule, wherein each gRNA molecule of the composition is complementary to a different target sequence.
8. The composition of any one of claims 5 to 7, further comprising a template nucleic acid.
9. The ition of claim 8, wherein the template c acid encodes a chimeric antigen receptor (CAR).
10. The composition of claim 9, wherein the CAR is: (a) a CD19 CAR; (b) a BCMA CAR; (c) a CD20 CAR; (d) a CD22 CAR; (e) a CD123 CAR; (f) an EGFRvIII CAR; or (g) a mesothelin CAR.
11. A nucleic acid comprising a sequence that encodes a gRNA molecule of any one of claims 1 to 4.
12. A vector comprising the nucleic acid of claim 11.
13. An o method of altering a target sequence of a cell, comprising contacting said cell with: (a) a gRNA le of any one of claims 1 to 4 and a Cas9 molecule; (b) a gRNA molecule of any one of claims 1 to 4 and nucleic acid encoding a Cas9 molecule; (c) a nucleic acid encoding a gRNA molecule of any one of claims 1 to 4 and a Cas9 (d) a nucleic acid encoding a gRNA molecule of any one of claims 1 to 4 and a nucleic acid encoding a Cas9 molecule; (e) any of a) to d), above, and a template nucleic acid; (f) any of a) to d) above, and nucleic acid comprising sequence encoding a template nucleic acid; or (g) the composition of any one of claims 5 to 10.
14. The ex-vivo method of claim 13, n the gRNA molecule or nucleic acid encoding the gRNA molecule, and the Cas9 molecule or nucleic acid encoding the Cas9 molecule, are formulated in a single composition or more than one composition.
15. An ex-vivo method of preparing cells for immunotherapy comprising modifying cells to reduce or ate expression of TRAC by ucing into said cells a gRNA molecule of any one of claims 1 to 4, and wherein the method further comprises expanding said cells.
16. The ex-vivo method of claim 15, wherein the method further comprises introducing a template c acid to the cells, wherein the template nucleic acid comprises a nucleic acid sequence encoding a chimeric antigen receptor (CAR).
17. Use of the gRNA molecule of any one of claims 1 to 4, the composition of any one of claims 5 to 10, the nucleic acid of claim 11, or the vector of claim 12 in the manufacture of a medicament for treating a disease associated with expression of a tumor antigen or providing an umor immunity in a subject. o k m g Q & 03°" .Q ®@.®§a. W E m m m g *2“ m! 69% g? gm E? w £3 E ' :3 “ 3? a ”E g...“ as: 3%,. m mum E wags...“ 5m WNW ‘3 EELS“ m g E a; N ?g? ? 3 Wa‘ g 100 C3 C3 C3 C3 C23 GD (0 '6' N {gm} aa M32951 HEW SUBSTITUTE SHEET (RULE 26) ma?a; Maze: \\\\\\\\\\\\\\\\\\\\\g m?hmw gated Mém‘sms?asamg ________ _____ _____ SUBSTITUTE SHEET (RULE 26) E 1.3 Day 3322*; 74 74 \
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ782859A NZ782859B2 (en) | 2016-12-02 | Compositions and methods for immunooncology | |
| NZ782849A NZ782849B2 (en) | 2016-12-02 | Compositions and methods for immunooncology | |
| NZ782855A NZ782855B2 (en) | 2016-12-02 | Compositions and methods for immunooncology | |
| NZ782858A NZ782858B2 (en) | 2016-12-02 | Compositions and methods for immunooncology | |
| NZ782857A NZ782857B2 (en) | 2016-12-02 | Compositions and methods for immunooncology |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263169P | 2015-12-04 | 2015-12-04 | |
| US201662316784P | 2016-04-01 | 2016-04-01 | |
| US201662394290P | 2016-09-14 | 2016-09-14 | |
| NZ74388716 | 2016-12-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ758480A true NZ758480A (en) | 2025-07-25 |
| NZ758480B2 NZ758480B2 (en) | 2025-10-29 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551907A1 (en) | Antagonizing cd73 antibody | |
| PH12020551317A1 (en) | Anti-cd73 antibodies and methods of use thereof | |
| MX2022007575A (en) | Anti-cd73 antibodies and uses thereof. | |
| IL258215B (en) | An anti-mesothelin antibody, encoding said nucleic acid, a vector consisting of said nucleic acid, a host cell consisting of said vector, a preparation method of said antibody, and a pharmaceutical antibody | |
| PE20200839A1 (en) | ANTI-CD137 ANTIBODIES | |
| WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| IL268620B1 (en) | Anti-lag3 antibodies, pharmaceutical formulations comprising them and uses thereof for treating cancer | |
| EP4389226A3 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| MX2021013219A (en) | CELLS EXPRESSING A RECOMBINANT RECEPTOR OF A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS. | |
| IL295858B1 (en) | gRNA MOLECULES COMPRISING A TRACR AND A crRNA, COMPOSITION COMPRISING THE SAME AND THEIR USE | |
| NZ783534A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| PE20191717A1 (en) | ANTI-TRBC1 ANTIGEN UNION DOMAIN | |
| PH12017500918A1 (en) | Antibodies against cd73 and uses thereof | |
| JP2018520654A5 (en) | ||
| PH12021552790A1 (en) | Materials and methods for modulating t cell mediated immunity | |
| WO2017040344A3 (en) | Chimeric polypeptide assembly and methods of making and using the same | |
| PL422231A1 (en) | CAR immune cells for cancer treatment | |
| NZ609916A (en) | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
| WO2020070678A3 (en) | Antibodies specific for human and cynomolgus apoc3 and methods of use thereof | |
| WO2021163562A3 (en) | Compositions and methods comprising splicing-derived antigens for treating cancer | |
| MX2025012294A (en) | Multispecific antibody targeting c-met | |
| WO2020084102A3 (en) | Oncolytic virotherapy and immunotherapy | |
| MX2025000487A (en) | Anti-mesothelin antibodies | |
| NZ758480B2 (en) | Compositions and methods for immunooncology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2026 BY COMPUTER PACKAGES INC Effective date: 20251126 |